{"entity":{"id":"nct04847505","kind":"trial","name":"68Ga-DOTA-TATE PET/CT Imaging in NETs","aka":[],"tldr":"A phase 3 trial of Gallium-68 DOTATATE in Neuroendocrine tumours, run by Centre de recherche du Centre hospitalier universitaire de Sherbrooke, with a status the registry has not verified recently.","summary":"68Ga-DOTA-TATE PET/CT Imaging in NETs is a phase 3 interventional study registered as NCT04847505 by Centre de recherche du Centre hospitalier universitaire de Sherbrooke, with 5000 participants planned, started 2020-01-01 and due to reach its primary completion in 2025-12-31. Interventions recorded: 68Ga-DOTA-TATE. Conditions recorded: Neuroendocrine Tumors.\n\nLinked to the drug Gallium-68 DOTATATE because the registry names it among its interventions and Neuroendocrine tumours among its conditions. Registry record only: no result has been read by an editor.","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT04847505","url":"https://clinicaltrials.gov/study/NCT04847505"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["neuroendocrine"],"sections":[],"technologies":[],"targets":[],"drugs":["ga68-dotatate"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04847505","phase":"3","setting":"Pragmatic Study on the Use of 68Ga-DOTA-TATE PET|CT Imaging as a Standard of Care to Influence Clinical Management","sponsor":"Centre de recherche du Centre hospitalier universitaire de Sherbrooke","participation":[{"nct":"NCT04847505","source":"https://clinicaltrials.gov/study/NCT04847505","fetchedAt":"2026-10-07T16:53:29.376Z","studySha256":"48273d0caceaddc4dd1737952161f85116666cdeec63c8082202f958596f3ce9","overallStatus":"UNKNOWN","lastUpdatePosted":"2024-07-18","leadSponsor":"Centre de recherche du Centre hospitalier universitaire de Sherbrooke","collaboratorCount":2,"sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":5000,"enrolmentType":"ESTIMATED","siteCount":2,"recruitingSiteCount":2,"countries":["Canada"]}],"started":"2020-01-01","startedType":"actual","enrolled":5000,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04847505/","neighbours":{"cancer":[{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"}],"drug":[{"id":"ga68-dotatate","kind":"drug","name":"Gallium-68 DOTATATE (and Cu-64 DOTATATE)","route":"/drugs/ga68-dotatate/"}]}}